ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2022

Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in Patients with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the UK.

Rory J McCrimmon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.